Trxade Group, Inc. (NASDAQ: MEDS), an integrated drug
procurement, delivery and healthcare platform, today announced that its
wholly-owned subsidiary, Integra Pharma Solutions, has filed for an Emergency
Use Authorization (“EUA”) with the U.S. Food and Drug Administration (“FDA”) in
collaboration with its partnered manufacturer of the SARS-CoV-2 IgM/IgG
Antibody Rapid Test Kit. Under section 564 of the Federal Food, Drug, and
Cosmetic Act (FD&C Act), the FDA Commissioner may, in an emergency, allow
unapproved medical products or unapproved uses of approved medical products to
be used in the diagnosis, treatment or prevention of serious or
life-threatening diseases or when there are no adequate, approved, and
available alternatives. The EAU filing has dual purposes; first serving as FDA
notification that Trxade Group will be distributing the test and, secondly, if
the EUA is approved, it enables Trxade Group to market the product for
diagnostic use. Currently, the test is intended to aid in presenting a qualitative
overview of antibody presence in patients who have possibly been infected by
the Coronavirus (COVID-19).
To view the full press release, visit http://ibn.fm/vzMQz
About Trxade Group, Inc.
Headquartered in Tampa, Florida, Trxade Group, Inc. (NASDAQ:
MEDS) is an integrated drug procurement, delivery and healthcare platform that
enables price transparency and increased profit margins to buyers and sellers
of pharmaceuticals, makes Healthcare services affordable and accessible across
all 50 states, and steps in to meet today’s immediate demands. Founded in 2010,
Trxade Group is comprised of four synergistic operating platforms: the Trxade
B2B trading platform with 12,100 registered pharmacies, a licensed virtual
Wholesaler, affordable healthcare via its Bonum Health app or web-based
telehealth services, and Same Day or Mail Order Pharmacy delivery capabilities
via its DelivMeds app featuring its extensive nationwide distribution network.
For additional information, please visit www.Trxade.com.
NOTE TO INVESTORS: The latest news and updates
relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions and
agreements to conference attendance and clinical study results, our news breaks
keep you up-to-date with the day’s top movers. MissionIR is primarily focused
on strategic communications. We have executed countless communications programs
to address the needs of companies ranging from start-ups to established
industry leaders, gaining valuable experience and the expertise necessary to
determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
